Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 250

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 250
---
 504 shares of common stock at a weighted average price of $436.00. 157 As of October 1, 2024, the board of directors has approved option awards to the executive officers for 2024, as set forth below:

| Name and Position                        |     | Stock   
 Options |        |
| Chris Ehrlich,                           
 Chief Executive Officer and Chairman (1) |     |         | 25,500 |
| Andrew “Al”                              
 Kucharchuk, Chief Financial Officer      |     |         |  5.000 |
| Kristen Pierce, Chief                    
 Development Officer                      |     |         |  2,659 |
| Brian G. Atwood, Former                  
 Chief Executive Officer and Chairman (2) |     |         |  5,080 |
| Charles R. Carter, Former                
 Chief Financial Officer (3)              |     |         |      - |
| Daniel Corey, M.D.,                      
 Former Chief Technology Officer (4)      |     |         |      - |

| (1) | Excludes 5,272 options                                                  
 granted under the 2024 Plan which were forfeited on September 30, 2024. |
| (2) | Excludes 13,318 options                                                 
 granted under the 2024 Plan which were forfeited on September 30, 2024. |
| (3) | Excludes 4,954 options                                                  
 granted under the 2024 Plan which were forfeited on September 30, 2024. |
| (4) | Excludes 4,613 options                                                  
 granted under the 2024 Plan which were forfeited on September 23, 2024. |

Compensation Recovery Policy Our board of directors adopted a Compensation Recovery Policy (the “Compensation Recovery Policy”), in compliance with the Nasdaq listing rules, which requires recovery from executive officers of incentive-based compensation that is earned, granted or vested based on the achievement of a financial reporting measure in the event of a required accounting restatement of previously issued financial statements. The recoverable compensation includes any compensation received after the effective date of the Compensation Recovery Policy and in the three-year fiscal period preceding the date we were required to prepare the accounting restatement that is in excess of the amount that would have been earned, paid or vested had it been calculated based on the restated financial statements. Recovery is required regardless of fault or a covered officer’s role in the financial reporting process. The Compensation Recovery Policy is filed as Exhibit